Overview


According to FutureWise analysis the market for ankylosing spondylitis in 2023 is US$ 5.82 billion, and is expected to reach US$ 11.2 billion by 2031 at a CAGR of 8.52%.

Ankylosis spondylitis is a form of arthritis that leads to inflammation of the spine joints and ligaments and affects the peripheral joints, like the joints of the hips, knees, and ankles. These spinal ligaments and joints typically facilitate movement and flexibility. However, individuals with ankylosing spondylitis can feel joint stiffness due to inflammation. In severe cases, this can lead to fusion of vertebrae, which causes more rigidity and less flexibility in the spine. Furthermore, additional symptoms may arise based on which the condition impacts other body parts. Some may develop conditions like uveitis (eye disease), psoriasis (skin disease), or inflammatory bowel disease (gut disease). The most prevalent symptom of ankylosing spondylitis is lower back and hip pain accompanied by stiffness. Over time, these symptoms may extend to other regions of the spine or body. The pain usually intensifies during rest or inactivity, potentially causing increased discomfort at night or after prolonged sitting. Typically, movement and exercise can help alleviate pain.

No significant cure for ankylosing spondylitis exists, but numerous treatment interventions can effectively manage the symptoms. Encompassing therapies and physical and occupational therapies can aid mobility and posture. Some medications are also prescribed, which can alleviate the pain, control inflammation, improve posture and body positioning, and slow the disease progression. With proper treatment, most individuals with ankylosing spondylitis can lead productive lives.

FutureWise Market Research has published a report that provides an insightful analysis of Ankylosing Spondylitis Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Ankylosing Spondylitis Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • AbbVie Inc.
  • Janssen Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sandoz International GmbH.
  • Amgen Inc.
  • Protalix BioTherapeutics, Inc.
  • Reliance Life Sciences Pvt. Ltd.
  • Momenta Pharmaceuticals Inc.
  • Celgene Corporation
  • Regeneron Pharmaceuticals
  • MerckCo. Inc.
  • Johnson and Johnson Services, Inc.
  • UCB Inc.
  • Novartis AG
  • Samsung Bioepis Co., Ltd.
  • Biothera Pharmaceuticals, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug

  • Cosentyx
  • Humira
  • Simponi
  • Remicade
  • Embrel
  • Cimzia

By Molecule Type

  • Small Molecules
  • Biologics
  • Biosimilars

By Route of Administration

  • Oral
  • Parenteral

By End User

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

The market is categorized into drug, molecule type, route of administration, end user and region. The drug segment is fragmented into Cosentyx, Humira, Simponi, Enbrel and Cimzia. The Humira drug is estimated to hold the largest ankylosing spondylitis market share and this is credited to its high efficacy and low cost. The Cosentyx, however, it predicted to grow at a substantial rate during the forecasted timeframe owing to the expiration of patents in the European region. The end user segment is classified into hospitals, clinics and others.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key market trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Ankylosing Spondylitis Market By Drug, By Molecule Type, By Route of Administration, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers, and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Molecule Typeology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Ankylosing Spondylitis Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Ankylosing Spondylitis Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Ankylosing Spondylitis Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Ankylosing Spondylitis Market, By Drug Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cosentyx
        2. Humira
        3. Simponi
        4. Remicade
        5 . Embrel
        6 . Cimzia

  • 8.   Ankylosing Spondylitis Market, By Molecule Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Small Molecules
        2. Biologics
        3. Biosimilars

  • 9.   Ankylosing Spondylitis Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Parenteral

  • 10.   Ankylosing Spondylitis Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinics
        3. Others

  • 11.   North America Ankylosing Spondylitis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Ankylosing Spondylitis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Ankylosing Spondylitis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Ankylosing Spondylitis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Drugs Offered and Financial Layouts)
    •   1. AbbVie Inc.
         1.1. Company Overview
         1.2. Drug Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Janssen Pharmaceuticals Inc.
         2.1. Company Overview
         2.2. Drug Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Pfizer Inc.
         3.1. Company Overview
         3.2. Drug Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Sandoz International GmbH.
         4.1. Company Overview
         4.2. Drug Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Amgen Inc.
         5.1. Company Overview
         5.2. Drug Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Protalix BioTherapeutics, Inc.
         6.1. Company Overview
         6.2. Drug Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Reliance Life Sciences Pvt. Ltd.
         7.1. Company Overview
         7.2. Drug Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Momenta Pharmaceuticals Inc.
         8.1. Company Overview
         8.2. Drug Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Celgene Corporation
         9.1. Company Overview
         9.2. Drug Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Regeneron Pharmaceuticals
         10.1. Company Overview
         10.2. Drug Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. MerckCo. Inc.
         11.1. Company Overview
         11.2. Technology Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Johnson and Johnson Services, Inc. 
                   12.1. Company Overview
         12.2. Technology Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. UCB Inc.
         13.1. Company Overview
         13.2. Technology Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Novartis AG
         14.1. Company Overview
         14.2. Technology Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Samsung Bioepis Co., Ltd.
         15.1. Company Overview
         15.2. Technology Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Biothera Pharmaceuticals, Inc.
         16.1. Company Overview
         16.2. Technology Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients